STUDY PROTOCOL article
Front. Aging Neurosci.
Sec. Neurocognitive Aging and Behavior
Volume 17 - 2025 | doi: 10.3389/fnagi.2025.1584115
Protocol of a Randomized, Single-Blind, Controlled Trial of an 18-Month, Home-Based, High-Intensity, Exercise Intervention in Older, Cognitively Unimpaired APOE e4 Carriers
Provisionally accepted- 1Cleveland Clinic, Cleveland, Ohio, United States
- 2University of Washington, Seattle, Washington, United States
- 3University of Maryland, Baltimore, Maryland, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The World Health Organization highlighted the potential protective role of exercise against cognitive decline, all-cause dementia, Alzheimer's disease (AD), and vascular dementia in healthy individuals. We have previously shown that exercise is particularly beneficial for older, cognitively unimpaired apolipoprotein E4 (APOE e4) carriers. A key unanswered question is whether a long-term, high-intensity aerobic exercise intervention initiated in a cohort of previously inactive older individuals at genetic risk for AD has neuroprotective properties. Design: CYCLE-AD is a randomized, single-blind, single-center, controlled trial of a home-based, high-intensity exercise intervention involving 150 older e4 carriers (ages 65-80 years) who are healthy, cognitively unimpaired, and physically inactive. Participants are randomized into two groups: Indoor Cycling (IC) or Usual and Customary Care (UCC) (target of 75 each). IC participants exercise 3x/week on an upright stationary cycle ergometer at a moderate-vigorous intensity for 18 months. Those in the UCC group are expected to maintain enrollment levels of activity.Outcomes: Comparison of IC and UCC groups on change in primary and secondary outcomes over baseline, 9-month, and 18-month evaluations. Primary outcomes are VO2peak (Fitness), 5-trial total recall on the Rey Auditory Verbal List Learning Test (Episodic Memory), and total hippocampal volume derived from structural MRI (Brain Atrophy). Secondary outcomes include comprehensive neurocognitive and physical function test batteries, MRI scans including structural and functional connectivity measures, and blood-based biomarkers. Hypotheses: Over an 18-month interval, physically inactive e4 carriers who engage in high-intensity aerobic exercise will demonstrate less cognitive decline and hippocampal atrophy than physically inactive e4 carriers who did not participate in a formal exercise program. Conclusion: Successful demonstration of a scalable, home-based, high-intensity aerobic exercise intervention in altering the trajectory of AD pathophysiology and its effects on cognitive functioning will transform AD treatment, improve patient outcomes and quality of life, and reduce health care costs. ClinicalTrials.com registration number: NCT04748861
Keywords: Alzheimer's disease, Exercise, Neuroprotection, APOE e4, randomized clinical trial
Received: 26 Feb 2025; Accepted: 25 Apr 2025.
Copyright: © 2025 Rao, Chorba, Helppi, Tuladhar, Penko, Holley, Nehls, Paulino, Streicher, Zhu, Bruening, Durgerian, Koenig, Lowe, Jones, Galioto, Pillai, Bekris, Leverenz, Rosenfeldt, Singh, Beck, Smith and Alberts. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Stephen M Rao, Cleveland Clinic, Cleveland, 44195, Ohio, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.